Arrowhead Research
ARWR
$87.11
-0.41%
Arrowhead Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing RNA interference (RNAi) therapies for diseases with genetic origins or protein overexpression, targeting areas such as cardiometabolic, neuromuscular, pulmonary, and liver diseases. As a pioneer in RNAi therapeutics, Arrowhead distinguishes itself through its proprietary targeted delivery platforms and a robust pipeline of clinical candidates. The current investor narrative centers on the company's transformative growth, driven by recent clinical successes and strategic partnerships, which have propelled the stock to multi-year highs and attracted significant analyst attention. However, the company's financial performance remains volatile, with recent quarters swinging between profitability and losses, reflecting the lumpy nature of milestone-based revenues and ongoing R&D investments.…
ARWR
Arrowhead Research
$87.11
Related headlines
Investment Opinion: Should I buy ARWR Today?
Based on the data, ARWR is rated a Buy. The consensus Strong Buy rating (mean 1.33) and average target of $110.18 imply 26.5% upside, and the company's RNAi platform has multiple catalysts that could drive significant value. The thesis is that Arrowhead's proprietary delivery technology and pipeline will translate into commercial success, justifying the forward P/S of 2.26x.
Sign up to view all
ARWR 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The combination of a strong analyst consensus, expected revenue acceleration, and a discounted forward P/S relative to peers supports a positive outlook. However, the extreme volatility in financial results and high beta warrant caution. The stance would be upgraded to high confidence if the company delivers consistent revenue growth and positive cash flow, while a downgrade would occur if clinical setbacks or revenue disappointments emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Arrowhead Research's 12-month outlook, with a consensus price target around $110.18 and implied upside of +26.5% versus the current price.
Average Target
$110.18
0 analysts
Implied Upside
+26.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$100 - $126
Analyst target range
Arrowhead is covered by 11 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.33). The average price target is $110.18, implying approximately 26.5% upside from the current price of $87.11. The distribution is bullish, with no sell ratings and a majority of buys, reflecting strong confidence in the company's pipeline and growth prospects. The target price range spans from $100.00 low to $126.00 high, a spread of 26%, indicating moderate uncertainty. The high target of $126 assumes successful commercialization of lead candidates and significant revenue growth, while the low target of $100 still implies upside, suggesting analysts see limited downside risk. Recent ratings actions include upgrades from Morgan Stanley (Equal Weight to Overweight) and reiterations of Buy from HC Wainwright and Chardan, signaling positive sentiment. The wide range reflects the inherent volatility of biotech catalysts, but the overall bullish stance underscores the market's optimism about Arrowhead's RNAi platform.
Bulls vs Bears: ARWR Investment Factors
Arrowhead presents a classic high-risk, high-reward biotech investment. The bull case is anchored by a Strong Buy analyst consensus, a robust pipeline, and expectations of explosive revenue growth, while the bear case highlights extreme financial volatility, negative cash flow, and valuation concerns. Currently, the bull side has stronger evidence given the 26.5% upside to analyst targets and the potential for multiple clinical catalysts. The central tension is whether the company can convert its RNAi platform into consistent commercial revenue, which would justify the current valuation and propel the stock higher, or whether continued lumpiness and R&D costs will keep it in a boom-bust cycle.
Bullish
- Strong Buy consensus with 26.5% upside: 11 analysts rate ARWR a Strong Buy (mean 1.33) with an average target of $110.18, implying 26.5% upside from $87.11. No sell ratings and a low target of $100 still above current price, indicating limited downside per sell-side.
- Revenue growth expected to surge: Forward P/S of 2.26x based on estimated revenue of $2.04B implies the market expects a massive revenue jump from the trailing $73.7M quarter. Analysts estimate revenue could reach $3.54B in the best case, reflecting pipeline commercialization potential.
- Proprietary RNAi platform with multiple catalysts: Arrowhead's targeted delivery platforms and pipeline across cardiometabolic, neuromuscular, and liver diseases provide multiple shots on goal. Recent upgrades from Morgan Stanley and reiterations from HC Wainwright and Chardan signal positive clinical momentum.
- Strong liquidity and manageable debt: Current ratio of 4.86 and debt-to-equity of 0.786 indicate solid liquidity to fund operations. The company raised $221.7M from equity issuance in Q2 FY2026, bolstering its cash position for R&D.
Bearish
- Extreme revenue volatility and losses: Q2 FY2026 revenue fell 86.4% YoY to $73.7M, swinging from a $370.4M profit in Q2 FY2025 to a $132.7M loss. This lumpiness from milestone payments makes financial performance unpredictable and hard to value.
- Negative free cash flow and TTM losses: TTM free cash flow is -$50.9M, and trailing EPS is -$0.00035, indicating the company is not yet self-sustaining. ROE is -0.35% and ROA is -8.1%, reflecting ongoing losses despite revenue spikes.
- High valuation multiples on trailing metrics: Trailing P/S of 5.56x and EV/Sales of 18.13x are elevated, though below industry average. PEG ratio of 28.34 suggests the stock is expensive relative to near-term growth expectations.
- Beta of 1.294 amplifies market swings: ARWR is ~30% more volatile than the market, with a max drawdown of -24.64% over the past year. This makes it susceptible to sharp corrections in risk-off environments, as seen in the July 2026 drop from $86.55 to $71.82.
ARWR Technical Analysis
Arrowhead's stock is in a powerful long-term uptrend, with a 1-year price change of +319.8%, dramatically outperforming the S&P 500's +20.5% gain over the same period. The current price of $87.11 sits at 87.4% of the 52-week range (low $20.445, high $95.49), indicating the stock is trading near its highs, a sign of strong momentum but also potential overextension. The stock's beta of 1.294 suggests it is about 30% more volatile than the market, which is typical for a high-growth biotech and implies amplified swings in both directions.
Beta
1.29
1.29x market volatility
Max Drawdown
-24.6%
Largest decline past year
52-Week Range
$20-$95
Price range past year
Annual Return
+319.8%
Cumulative gain past year
| Period | ARWR Return | S&P 500 |
|---|---|---|
| 1m | -1.8% | +3.6% |
| 3m | +16.2% | +2.7% |
| 6m | +37.0% | +11.4% |
| 1y | +319.8% | +18.7% |
| ytd | +28.5% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ARWR Fundamental Analysis
Revenue has been highly erratic, with the most recent quarter (Q2 FY2026, ended March 31, 2026) reporting $73.7 million, a steep 86.4% decline year-over-year, following a strong Q1 FY2026 with $264.0 million and a robust Q2 FY2025 with $542.7 million. This volatility stems from the recognition of large milestone payments from partnerships, which are lumpy and not indicative of underlying operational trends. The company's profitability is equally inconsistent: Q2 FY2026 posted a net loss of $132.7 million (EPS -$0.93), while Q1 FY2026 was profitable with net income of $30.8 million (EPS $0.22), and Q2 FY2025 saw a massive $370.4 million profit (EPS $2.75) due to a one-time licensing deal. Gross margin is 100% as the company recognizes all revenue as gross profit, typical for biotech licensing models, but operating margins swung from -191.6% in Q2 FY2026 to +15.5% in Q1 FY2026, highlighting the lack of stable profitability. The balance sheet shows a debt-to-equity ratio of 0.786 and a current ratio of 4.86, indicating adequate liquidity, but free cash flow was negative at -$50.9 million on a TTM basis, though the most recent quarter generated positive operating cash flow of $84.4 million, suggesting some improvement. ROE is -0.35% and ROA is -8.1%, reflecting the recent losses, but the company has raised substantial capital through equity offerings, as seen in the $221.7 million from common stock issuance in Q2 FY2026, to fund its pipeline.
Quarterly Revenue
$73737000.0B
2026-03
Revenue YoY Growth
-86.4%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$-50872000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ARWR Overvalued?
Given that Arrowhead's trailing twelve-month net income is negative (EPS -$0.00035), the P/E ratio is not meaningful, so we use the price-to-sales (P/S) ratio as the primary valuation metric. The trailing P/S is 5.56x, while the forward P/S (based on estimated revenue of $2.04 billion) is approximately 2.26x, implying the market expects significant revenue growth. Compared to the biotechnology industry average P/S of around 8-10x, Arrowhead trades at a discount, which may reflect the lumpiness of its revenue and the early stage of its commercial products. Historically, the stock's P/S has ranged from as low as 3.13x in Q2 2025 to as high as 121x in Q2 2026, and the current 5.56x is near the lower end of that range, suggesting the market is pricing in more conservative expectations despite the recent rally.
PE
-2827.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Arrowhead's primary risk is its dependence on lumpy milestone payments, which caused revenue to swing from $542.7M in Q2 FY2025 to $73.7M in Q2 FY2026, an 86.4% decline. This volatility leads to inconsistent profitability, with a net loss of $132.7M in the latest quarter and negative TTM free cash flow of -$50.9M. The company's debt-to-equity of 0.786 and interest expense of $23.8M per quarter add financial drag, though the current ratio of 4.86 provides a cushion. Continued reliance on equity issuance, such as the $221.7M raised in Q2 FY2026, could dilute shareholders if cash burn persists.
FAQ
The key risks are: 1) Financial risk from revenue volatility and negative free cash flow, as seen in the 86.4% YoY revenue decline in Q2 FY2026; 2) Clinical and regulatory risk, as a trial failure could erase significant value; 3) Market risk from high beta (1.294) and potential valuation compression; 4) Competitive risk from other RNAi companies like Alnylam. The most severe risk is a clinical failure, which could lead to a -76.5% decline to the 52-week low.
The 12-month forecast is bullish, with a base case target of $100-110 (50% probability) and a bull case target of $110-126 (30% probability). The bear case target is $60-80 (20% probability), reflecting downside risks. The most likely scenario is the base case, which assumes continued pipeline progress and revenue growth, leading to a stock price around the analyst average of $110.18, a 26.5% upside from current levels.
ARWR's trailing P/S of 5.56x is below the biotech industry average of 8-10x, suggesting it is undervalued on a trailing basis. However, the forward P/S of 2.26x implies the market expects a massive revenue increase to $2.04B, which may be optimistic given the lumpy revenue history. The PEG ratio of 28.34 indicates the stock is expensive relative to near-term growth, but this is common for biotech companies with high potential. Overall, the stock appears fairly valued to slightly undervalued if the pipeline delivers, but overvalued if revenue growth disappoints.
ARWR is a good buy for investors with a high risk tolerance and a long-term horizon, given the 26.5% upside to the analyst average target of $110.18 and the Strong Buy consensus. However, the stock is highly volatile (beta 1.294) and has negative TTM free cash flow, so it is not suitable for conservative investors. The biggest downside risk is a clinical failure, which could send the stock to the 52-week low of $20.445, a -76.5% loss. For those who believe in the RNAi platform and can withstand volatility, the risk/reward is attractive.
ARWR is better suited for long-term investment (3-5 years) due to its early-stage pipeline and high volatility. Short-term trading is possible given the stock's momentum, but the beta of 1.294 and max drawdown of -24.64% make it risky for short-term investors. The company's growth stage and lack of dividends mean investors should be prepared for significant price swings. A minimum holding period of 3 years is recommended to allow clinical catalysts to play out.